Johnson & Johnson (J&J) has reported encouraging results from a Phase I study of the investigational intravesical drug-releasing system, Erda-iDRS (erdafitinib).
The trial targets patients with intermediate-risk and high-risk non–muscle-invasive bladder cancer (NMIBC) harbouring select fibroblast growth factor receptor (FGFR) alterations.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The multi-centre, open-label trial met its primary safety endpoint, showed durable, complete responses in intermediate-risk patients, and encouraging recurrence-free outcomes in high-risk disease.
Data were presented at the European Association of Urology 2026 Annual Meeting.
Erda-iDRS delivers erdafitinib directly into the bladder via intravesical administration over three months, enabling localised therapy to minimise systemic exposure and adverse events associated with oral administration.
As of 3 November 2025, 62 recurrent intermediate-risk NMIBC patients and 26 recurrent, Bacillus Calmette-Guérin-experienced high-risk NMIBC patients received Erda-iDRS.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSafety was the primary endpoint, while secondary endpoints assessed complete response rate and duration for intermediate-risk cases and recurrence-free survival for high-risk cases.
In intermediate-risk patients receiving non-surgical treatment for visible tumours, the complete response rate was 89% within the initial treatment period. The median complete response duration was 18 months, with a median follow-up of 18 months. 49% of these patients are still being monitored.
Among high-risk patients treated with Erda-iDRS, median recurrence-free survival was 20 months, and the 12-month recurrence-free survival rate was 83%. Median follow-up in this group was 24 months, with 31% remaining under observation.
Treatment was found to be generally well tolerated, and no dose-limiting toxicities were reported. Local adverse events were most common, including haematuria and dysuria.
Four patients experienced grade three or higher adverse events related to treatment; eight patients discontinued due to adverse events; and two patients had serious treatment-related adverse events.
Pharmacokinetic data showed sustained urinary drug levels and minimal systemic exposure without observed hyperphosphataemia.
J&J bladder cancer disease area leader Christopher Cutie said: “For patients with FGFR-altered non–muscle-invasive bladder cancer, care has historically not been guided by precision-based approaches.
“The high and durable complete responses demonstrated with Erda-iDRS highlight the opportunity to deliver a targeted therapy to these patients. Bringing a biology-based approach into earlier stages of this disease has the potential to change how these patients are treated.”
Last month, J&J reported new findings from the QUASAR long-term extension study of Tremfya (guselkumab) for ulcerative colitis (UC).
